Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
.11 and Up!
»
ACTC--NEWS
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by BooDog: [QB] [QUOTE]Originally posted by BooDog: [qb] Convertibles. Toast? I highly doubt it. JMO. Would be nice to see some decent projections or study status news to absorb some of the conversions. [/qb][/QUOTE]Dude... News for 'ACTC' - (BioTime Names Dr. Michael D. West as CEO and Announces Entry Into Stem Cell Research and Regenerative Medicine) EMERYVILLE, Calif., Oct 11, 2007 (BUSINESS WIRE) -- BioTime, Inc. (OTCBB:BTIM) today announced that Michael D. West, Ph.D. has become BioTime's new Chief Executive Officer. Dr. West will help spearhead BioTime's entry into the field of regenerative medicine by developing advanced human stem cell products and technology for diagnostic, therapeutic and research use. Dr. West, who has served on the BioTime Board of Directors since 2002, has played a pioneering role in organizing the original collaborative effort to isolate human embryonic stem cells and in cloning and stem cell research. He has extensive academic and business experience in age-related degenerative diseases, telomerase molecular biology and human embryonic stem cell research and development. Prior to joining BioTime, Dr. West served as Director, President and Chief Scientific Officer of Advanced Cell Technology, Inc., a company engaged in developing human stem cell technology for use in regenerative medicine. Prior to Advanced Cell Technology, Inc., Dr. West founded Geron Corporation where he initiated and managed programs in telomerase diagnostics, telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase to immortalize human cells. He is an inventor named on over 60 patents and patent applications in the field of biotechnology and is an Adjunct Professor of Bioengineering at the University of California, Berkeley. Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. Degree in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. "The timing is right for important new business opportunities in the emerging field of regenerative medicine and stem cell research," said Michael D. West, Ph.D., BioTime's new Chief Executive Officer. "I couldn't be more enthusiastic about working with BioTime's experienced team, that has successfully navigated a therapeutic product, Hextend(R), through regulatory approval, and has brought its second product, PentaLyte(R), through a Phase II clinical trial. BioTime's goal will be to expand its research and development efforts into the new field of regenerative medicine, while continuing to develop and create markets for its line of blood plasma volume expander products." Regenerative medicine refers to therapies based on human embryonic stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. Embryonic stem cells are the first cells ever discovered that are capable of infinite cell division while possessing the potential to differentiate into all of the cell types of the human body. Stem cells may also have commercial uses in the development of experimental new drugs. "We are very excited to have Dr. West join BioTime as our new CEO," says Dr. Hal Sternberg, VP Research, and Member Office of the President. "We expect that his leadership capabilities and great expertise in human embryonic stem cell technology will enable BioTime to develop important innovative products for this rapidly expanding industry." In addition to entering this emerging field of medicine, BioTime will continue to seek new markets for its physiologically balanced blood plasma volume expander products. BioTime's lead product, Hextend(R), is distributed in the United States and South Korea and is undergoing clinical trials in Japan, while BioTime is continuing to offer licensing rights to Hextend in other countries. Hextend has become the standard plasma volume expander at a number of prominent teaching hospitals and leading medical centers and is part of the United States Armed Forces Tactical Combat Casualty Care protocol. PentaLyte(R) has undergone Phase II clinical testing in the United States and BioTime is now offering pharmaceutical companies in the U.S. and abroad the opportunity to license PentaLyte(R). BioTime plans to seek up to $5,000,000 of new funding to finance its operations and its entry into the stem cell field. BioTime has not yet determined the amount or terms of any securities that may be offered in connection with such financing. Any securities that may be offered have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. BioTime also plans to apply for research funding grants from private and public sources, including the California Institute for Regenerative Medicine ("CIRM"). CIRM was established in early 2005 with the passage of Proposition 71, the California Stem Cell Research and Cures Initiative. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was approved by California voters on November 2, 2004, and called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. CIRM will use bond proceeds to fund basic and applied biomedical research focused on developing diagnostics and therapies and on other vital research opportunities that will lead to life-saving medical treatments. All proposals are peer-reviewed to support the most promising scientific research. Research grants are made only to California-based research institutions. About BioTime, Inc. BioTime, headquartered in Emeryville, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine where it plans to develop new medical and research products using embryonic stem cell technology. Information about BioTime can be found on the web at [URL=http://www.biotimeinc.com.]www.biotimeinc.com.[/URL] Hextend(R) and PentaLyte(R) are registered trademarks of BioTime, Inc. Forward Looking Statements The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products, and the ability of BioTime to raise the capital needed to finance its current and planned operations. Other factors that could affect BioTime's operations and financial condition are discussed in BioTime's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission. SOURCE: BioTime, Inc. CONTACT: BioTime, Inc.Judith Segall, 510-350-2940 Copyright Business Wire 2007 -0- KEYWORD: United States North America California INDUSTRY KEYWORD: Health Biotechnology Clinical Trials -------------------------------------------- AND :D -------------------------------------------- News for 'ACTC' - (Advanced Cell Technology Announces the Promotion of Dr. Robert Lanza to Chief Scientific Officer Dr. Michael West Transitions to Non-Executive Director) LOS ANGELES, Oct 11, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB: ACTC) today announced the promotion of Dr. Robert Lanza, M.D., to the position of Chief Scientific Officer. Dr. Lanza joined Advanced Cell Technology in 1999 and has developed and managed several of the company's human embryonic stem cell (hESC) research programs including, but not limited to, the Retinal Pigment Epithelial (RPE) Cell Program, the Hemangioblast (HG) Cell Program and the Somatic Cell Nuclear Transfer (SCNT) research. Dr. Lanza will continue to work closely with Dr. Pedro Huertas, M.D., Ph.D., ACT's Chief Development Officer, to drive these hESC therapies to the clinical development stage. The company expects to file INDs for its RPE and HG Programs in 2008. Moreover, with the acquisition of Mytogen, Dr. Huertas and Dr. Lanza together with Dr. Jonathan Dinsmore, Ph.D., [b]expect ACT's Myoblast Program, an adult autologous stem cell therapy for the treatment of heart failure, to begin Phase II human clinical trials shortly, after having successfully completed four Phase I human clinical trials.[/b] Dr. Nabil Dib, an interventional cardiologist at University of California at San Diego's School of Medicine, will serve as a consultant to the company and lead the cellular transplantation process which is at the center of the Myoblast Program clinical trials. "We are excited to elevate Dr. Lanza to this position after his contributions to the company and look forward to his leadership and guidance," stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "Following the acquisition of Mytogen, Inc., we have streamlined this company to more effectively and expeditiously move our stem cell therapies from the research stage to the clinical trial phase of development. We believe the combination of Dr. Lanza, Dr. Huertas and Dr. Dinsmore provide us with a world-class research and development team." Dr. Lanza has over 25 years of research and industrial experience in stem cell research and regenerative medicine. From 1990 to 1998, he was Director of Transplantation Biology at BioHybrid Technologies, Inc., and is currently an Adjunct Professor at the Institute for Regenerative Medicine at Wake Forest University School of Medicine. Dr. Lanza has several hundred scientific publications and patents, and has authored and/or edited 20 books, including the Handbook of Stem Cells (as Editor-in-Chief), Principles of Tissue Engineering, XENO, Yearbook of Cell & Tissue Transplantation, and One World: The Health & Survival of the Human Species in the 21st Century (as editor, with forewords by C. Everett Koop and former President Jimmy Carter). He is a former Fulbright Scholar, and studied as a student in the laboratories of Richard Hynes (MIT), Jonas Salk (The Salk Institute), and Nobel laureates Gerald Edelman (Rockefeller University) and Rodney Porter (Oxford University). Dr. Lanza also worked closely and coauthored a series of papers with the late Harvard psychologist B.F. Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his B.A. and M.D. degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar. Simultaneous with Dr. Lanza's promotion, Advanced Cell Technology has announced that Michael D. West, Ph.D., is voluntarily stepping down as the company's President and Chief Scientific Officer to pursue new opportunities primarily relating to continued research on the ACTcellerate technology platform, which was exclusively developed by Dr. West. The company is in current discussions with several companies to license the ACTcellerate technology program. Dr. West will remain as a director of the company and has entered into a consulting arrangement through the end of 2007 to assist the company with certain scientific and intellectual property projects. "On behalf of the company, the board of directors, and the employees at Advanced Cell Technology, we want to thank Dr. West for his dedication and leadership and for all of the contributions he has made both to our company as well to the field of regenerative medicine." stated Mr. Caldwell. "I look forward to working with ACT in my consulting capacity to help move the first embryonic stem cell-derived products into the clinic," said Dr. Michael West. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts. For more information, visit [URL=http://www.advancedcell.com]www.advancedcell.com[/URL] Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. SOURCE: Advanced Cell Technology, Inc. CONTACT: Media:Chad Griffin Consulting, Inc.Jordan Markwith, 310-888-3523orInvestors:CEOcast, Inc.Andrew Hellman, 212-732-4300 Copyright Business Wire 2007 -0- KEYWORD: United States North America California Massachusetts INDUSTRY KEYWORD: Health Biotechnology You might think they read my post. lol :eek: :cool: :D [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2